| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SEVERINO MICHAEL | Vice Chairman | May 10 | Option Exercise | 59.60 | 100,000 | 5,960,468 | 252,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 10 | Sale | 152.28 | 100,000 | 15,227,966 | 152,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 09 | Option Exercise | 56.21 | 100,000 | 5,621,478 | 252,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 09 | Sale | 150.28 | 100,000 | 15,027,710 | 152,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 06 | Option Exercise | 54.55 | 100,000 | 5,454,790 | 252,103 | May 10 05:05 PM | | SEVERINO MICHAEL | Vice Chairman | May 06 | Sale | 150.81 | 100,000 | 15,080,612 | 152,103 | May 10 05:05 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Mar 24 | Option Exercise | 58.88 | 27,690 | 1,630,387 | 88,631 | Mar 25 05:09 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Mar 24 | Sale | 159.20 | 27,690 | 4,408,375 | 60,941 | Mar 25 05:09 PM | | Durkin Brian L | VP, Controller | Mar 09 | Option Exercise | 79.02 | 11,682 | 923,112 | 37,722 | Mar 11 05:05 PM | | Durkin Brian L | VP, Controller | Mar 09 | Sale | 150.01 | 18,628 | 2,794,301 | 19,094 | Mar 11 05:05 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Mar 01 | Sale | 148.26 | 15,000 | 2,223,836 | 41,623 | Mar 01 06:14 PM | | Michael Robert A. | Vice Chairman | Mar 01 | Sale | 148.25 | 43,105 | 6,390,247 | 37,877 | Mar 01 06:07 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Mar 01 | Sale | 147.29 | 25,000 | 3,682,189 | 16,623 | Mar 02 05:03 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Mar 01 | Sale | 148.25 | 21,488 | 3,185,599 | 60,941 | Mar 01 06:08 PM | | Strom Carrie C | SVP & Pres Global Allerg Aesth | Feb 07 | Sale | 141.17 | 2,396 | 338,243 | 42,499 | Feb 08 05:13 PM | | Durkin Brian L | VP, Controller | Dec 20 | Option Exercise | 61.36 | 7,180 | 440,565 | 28,295 | Dec 21 05:29 PM | | Durkin Brian L | VP, Controller | Dec 20 | Sale | 128.51 | 11,790 | 1,515,133 | 16,505 | Dec 21 05:29 PM | | Schumacher Laura J | Vice Chairman | Dec 17 | Option Exercise | 57.14 | 181,670 | 10,381,361 | 394,673 | Dec 21 05:21 PM | | Schumacher Laura J | Vice Chairman | Dec 17 | Sale | 130.24 | 181,670 | 23,660,678 | 213,003 | Dec 21 05:21 PM | | Stewart Jeffrey Ryan | EVP, Chief Commercial Officer | Dec 15 | Sale | 128.00 | 2,152 | 275,456 | 47,104 | Dec 17 05:01 PM | | Sorg Elaine K. | SVP, US Commercial Operations | Dec 13 | Sale | 125.85 | 6,458 | 812,739 | 0 | Dec 14 05:01 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Dec 09 | Option Exercise | 61.36 | 174,100 | 10,682,776 | 550,697 | Dec 10 05:02 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Dec 09 | Sale | 123.23 | 174,100 | 21,453,641 | 376,597 | Dec 10 05:02 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Dec 06 | Option Exercise | 58.88 | 50,350 | 2,964,608 | 50,350 | Dec 08 05:01 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Dec 06 | Sale | 120.00 | 50,350 | 6,042,000 | 0 | Dec 08 05:01 PM | | AUSTIN ROXANNE S | Director | Nov 03 | Sale | 117.23 | 20,000 | 2,344,600 | 49,284 | Nov 04 05:35 PM | | AUSTIN ROXANNE S | Director | Nov 02 | Sale | 116.38 | 51,844 | 6,033,384 | 69,284 | Nov 04 05:35 PM | | Sorg Elaine K. | SVP, US Commercial Operations | Aug 23 | Option Exercise | 114.36 | 7,080 | 809,669 | 18,675 | Aug 25 06:08 PM | | Sorg Elaine K. | SVP, US Commercial Operations | Aug 23 | Sale | 120.00 | 13,080 | 1,569,600 | 11,595 | Aug 25 06:08 PM | | Strom Carrie C | SVP & Pres Global Allerg Aesth | Aug 23 | Sale | 120.00 | 5,057 | 606,840 | 51,047 | Aug 25 06:08 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | May 24 | Option Exercise | 34.93 | 86,920 | 3,036,230 | 203,204 | May 26 05:20 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | May 24 | Sale | 116.29 | 86,920 | 10,108,033 | 116,284 | May 26 05:20 PM |
|
